Boothbay Fund Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Boothbay Fund Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-60,493	Closed	-$611K	–	2697
2022 Q4	$611K	Sell	60,493 -3,339	-5%	-$128	0.01%	1090
2022 Q3	$633K	Sell	63,832 -25,043	-28%	-$1.46K	0.02%	1104
2022 Q2	$880K	Buy	88,875 +57,641	+185%	+$11.9K	0.02%	876
2022 Q1	$308K	Buy	31,234 +15,323	+96%	+$4.89K	0.01%	1596
2021 Q4	$157K	Buy	15,911 +2,150	+16%	+$1.49K	﹤0.01%	1576
2021 Q3	$134K	Hold	13,761	–	–	﹤0.01%	1731
2021 Q2	$1K	Buy	+13,761	New	+$9.56K	﹤0.01%	1808

Boothbay Fund Management's BIOTW Position: Q1 2023 in Review

Boothbay Fund Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 60,493 shares — an estimated $611K sold.

Boothbay Fund Management first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $880K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Boothbay Fund Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Boothbay Fund Management sold 60,493 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $611K.
Boothbay Fund Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
Boothbay Fund Management's Biotech Acquisition Company Warrant position peaked at $880K in Q2 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.